A Simple Method for Assessment of Human Anti-Neu5Gc Antibodies Applied to Kawasaki Disease

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Padler Karavani, Vered ^a,d   Tremoulet, Adriana H ^b   Yu, Hai ^c   Chen, Xi ^c   Burns, Jane C ^b   Varki, Ajit ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LECTIN; N GLYCOLOYLNEURAMINIC ACID; N GLYCOLOYLNEURAMINIC ACID ANTIBODY; SIALOGLYCOPROTEIN; UNCLASSIFIED DRUG;

ACUTE DISEASE; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY ANEURYSM; CORONARY ARTERY THROMBOSIS; DISEASE MODEL; DISEASE SEVERITY; FEVER; HEART INFARCTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; IMMUNOREACTIVITY; INFLAMMATION; KNOCKOUT MOUSE; MASS SPECTROMETRY; MICROARRAY ANALYSIS; MOUSE; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; PROTEIN TARGETING; SERUM; WILD TYPE;

ANIMALS; ANTIBODIES; DISEASE MODELS, ANIMAL; EPITOPES; HUMANS; MICE; MICE, KNOCKOUT; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEURAMINIC ACIDS;

EID: 84874762936     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058443     Document Type: Article

References (50)

1. Schauer R, (2004) Sialic acids: fascinating sugars in higher animals and man. Zoology (Jena) 107: 49-64.
2. Angata T, Varki A, (2002) Chemical diversity in the sialic acids and related alpha-keto acids: an evolutionary perspective. Chem Rev 102: 439-469.
3. Chen X, Varki A, (2010) Advances in the biology and chemistry of sialic acids. ACS Chem Biol 5: 163-176.
4. Irie A, Suzuki A, (1998) CMP-N-acetylneuraminic acid hydroxylase is exclusively inactive in humans. Biochem Biophys Res Commun 248: 330-333.
5. Chou HH, Takematsu H, Diaz S, Iber J, Nickerson E, et al. (1998) A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc Natl Acad Sci USA 95: 11751-11756.
6. Hedlund M, Tangvoranuntakul P, Takematsu H, Long JM, Housley GD, et al. (2007) N-glycolylneuraminic acid deficiency in mice: implications for human biology and evolution. Mol Cell Biol 27: 4340-4346.
7. Davies LR, Pearce OM, Tessier MB, Assar S, Smutova V, et al. (2012) Metabolism of Vertebrate Amino Sugars with N-glycolyl Groups: Resistance of alpha2-8-linked N-glycolylneuraminic Acid to Enzymatic Cleavage. J Biol Chem 287: 28917-28931.
8. Naito Y, Takematsu H, Koyama S, Miyake S, Yamamoto H, et al. (2007) Germinal center marker GL7 probes activation-dependent repression of N-glycolylneuraminic acid, a sialic acid species involved in the negative modulation of B-cell activation. Mol Cell Biol 27: 3008-3022.
9. Bardor M, Nguyen DH, Diaz S, Varki A, (2005) Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J Biol Chem 280: 4228-4237.
10. Banda K, Gregg CJ, Chow R, Varki NM, Varki A, (2012) Metabolism of Vertebrate Amino Sugars with N-glycolyl Groups: Mechanisms underlying gastrointestinal Incorporation of the non-human sialic acid Xeno-autoantigen, N-glycolylneuraminic acid. J Biol Chem 287: 28852-28864.
11. Varki A, Gagneux P, (2012) Multifarious roles of sialic acids in immunity. Ann N Y Acad Sci 1253: 16-36.
12. Malykh YN, Schauer R, Shaw L, (2001) N-Glycolylneuraminic acid in human tumours. Biochimie 83: 623-634.
13. Zhu A, Hurst R, (2002) Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation 9: 376-381.
14. Ghaderi D, Taylor RE, Padler-Karavani V, Diaz S, Varki A, (2010) Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotechnol 28: 863-867.
15. Nguyen DH, Tangvoranuntakul P, Varki A, (2005) Effects of natural human antibodies against a nonhuman sialic acid that metabolically incorporates into activated and malignant immune cells. J Immunol 175: 228-236.
16. Padler-Karavani V, Yu H, Cao H, Chokhawala H, Karp F, et al. (2008) Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. Glycobiology 18: 818-830.
17. Lu Q, Padler-Karavani V, Yu H, Chen X, Wu SL, et al. (2012) LC-MS analysis of polyclonal human anti-Neu5Gc xeno-autoantibodies immunoglobulin G Subclass and partial sequence using multistep intravenous immunoglobulin affinity purification and multienzymatic digestion. Anal Chem 84: 2761-2768.
18. Taylor RE, Gregg CJ, Padler-Karavani V, Ghaderi D, Yu H, et al. (2010) Novel mechanism for the generation of human xeno-autoantibodies against the nonhuman sialic acid N-glycolylneuraminic acid. J Exp Med 207: 1637-1646.
19. Padler-Karavani V, Varki A, (2011) Potential impact of the non-human sialic acid N-glycolylneuraminic acid on transplant rejection risk. Xenotransplantation 18: 1-5.
20. Hedlund M, Padler-Karavani V, Varki NM, Varki A, (2008) Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progression. Proc Natl Acad Sci U S A 105: 18936-18941.
21. Padler-Karavani V, Hurtado-Ziola N, Pu M, Yu H, Huang S, et al. (2011) Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer. Cancer Res 71: 3352-3363.
22. Pham T, Gregg CJ, Karp F, Chow R, Padler-Karavani V, et al. (2009) Evidence for a novel human-specific xeno-auto-antibody response against vascular endothelium. Blood 114: 5225-5235.
23. Burns JC, Glode MP, (2004) Kawasaki syndrome. Lancet 364: 533-544.
24. Burns JC, (2007) The riddle of Kawasaki disease. N Engl J Med 356: 659-661.
25. Yellen ES, Gauvreau K, Takahashi M, Burns JC, Shulman S, et al. (2010) Performance of 2004 American Heart Association recommendations for treatment of Kawasaki disease. Pediatrics 125: e234-41.
26. Burns JC, (2009) Kawasaki Disease update. Indian J Pediatr 76: 71-76.
27. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, et al. (1991) A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324: 1633-1639.
28. Luca NJ, Yeung RS, (2012) Epidemiology and management of Kawasaki disease. Drugs 72: 1029-1038.
29. Matsubara T, Ichiyama T, Furukawa S, (2005) Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease. Clin Exp Immunol 141: 381-387.
30. Kawamori J, Miyake T, Yoshida T, (1989) B-cell function in Kawasaki disease and the effect of high-dose gamma-globulin therapy. Acta Paediatr Jpn 31: 537-543.
31. Lee HH, Park IH, Shin JS, Kim DS, (2009) Immunoglobulin V(H) chain gene analysis of peripheral blood IgM-producing B cells in patients with Kawasaki disease. Yonsei Med J 50: 493-504.
32. Giordani L, Quaranta MG, Marchesi A, Straface E, Pietraforte D, et al. (2011) Increased frequency of immunoglobulin (Ig)A-secreting cells following Toll-like receptor (TLR)-9 engagement in patients with Kawasaki disease. Clin Exp Immunol 163: 346-353.
33. Arita K, Ikuta K, Nishi Y, Kato S, Yamauchi E, et al. (1982) Heterophile Hanganutziu-Deicher antibodies in sera of patients with Kawasaki diseases. Biken J 25: 157-162.
34. Tamura T, Kano K, Milgrom F, (1984) Mixed agglutination with guinea pig tissue sediments for detection of heterophile antibodies. Diagn Immunol 2: 101-104.
35. Takiguchi M, Tamura T, Goto M, Kusakawa S, Milgrom F, et al. (1984) Immunological studies on Kawasaki disease. I. Appearance of Hanganutziu-Deicher antibodies. Clin Exp Immunol 56: 345-352.
36. Varki A, Diaz S, (1984) The release and purification of sialic acids from glycoconjugates: methods to minimize the loss and migration of O-acetyl groups. Anal Biochem 137: 236-247.
37. Padler-Karavani V, Song X, Yu H, Hurtado-Ziola N, Huang S, et al. (2012) Cross-comparison of protein recognition of sialic acid diversity on two novel sialoglycan microarrays. J Biol Chem 287: 22593-22608.
38. Hara S, Yamaguchi M, Takemori Y, Nakamura M, Ohkura Y, (1986) Highly sensitive determination of N-acetyl- and N-glycolylneuraminic acids in human serum and urine and rat serum by reversed-phase liquid chromatography with fluorescence detection. J Chromatogr 377: 111-119.
39. Goodarzi MT, Turner GA, (1998) Reproducible and sensitive determination of charged oligosaccharides from haptoglobin by PNGase F digestion and HPAEC/PAD analysis: glycan composition varies with disease. Glycoconjugate J 15: 469-475.
40. Kotani N, Takasaki S, (1997) Analysis of O-linked oligosaccharide alditols by high-pH anion-exchange chromatography with pulsed amperometric detection. Anal Biochem 252: 40-47.
41. North SJ, Hitchen PG, Haslam SM, Dell A, (2009) Mass spectrometry in the analysis of N-linked and O-linked glycans. Curr Opin Struct Biol 19: 498-506.
42. Norgard KE, Han H, Powell L, Kriegler M, Varki A, et al. (1993) Enhanced interaction of L-selectin with the high endothelial venule ligand via selectively oxidized sialic acids. Proc Natl Acad Sci USA 90: 1068-1072.
43. Smith DF, Song X, Cummings RD, (2010) Use of glycan microarrays to explore specificity of glycan-binding proteins. Methods Enzymol 480: 417-444.
44. Knibbs RN, Goldstein IJ, Ratcliffe RM, Shibuya N, (1991) Characterization of the carbohydrate binding specificity of the leukoagglutinating lectin from Maackia amurensis. Comparison with other sialic acid-specific lectins. J Biol Chem 266: 83-88.
45. Cheresh DA, Reisfeld RA, Varki A, (1984) O-Acetylation of disialoganglioside GD3 by human melanoma cells creates a unique antigenic determinant. Science 225: 844-846.
46. Sjoberg ER, Powell LD, Klein A, Varki A, (1994) Natural ligands of the B cell adhesion molecule CD22beta can be masked by 9-O-acetylation of sialic acids. J Cell Biol 126: 549-562.
47. Brinkman-Van der Linden ECM, Sonnenburg JL, Varki A, (2002) Effects of sialic acid substitutions on recognition by Sambucus nigra agglutinin and Maackia amurensis hemagglutinin. Anal Biochem 303: 98-104.
48. Galili U, (2005) The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. Immunol Cell Biol 83: 674-686.
49. Stoop JW, Zegers BJ, Sander PC, Ballieux RE, (1969) Serum immunoglobulin levels in healthy children and adults. Clin Exp Immunol 4: 101-112.
50. Zegers BJ, Stoop JW, Reerink-Brongers EE, Sander PC, Aalberse RC, et al. (1975) Serum immunoglobulins in healthy children and adults. Levels of the five classes, expressed in international units per millilitre. Clin Chim Acta 65: 319-329.